Ponalrestat (Standard)
Ponalrestat (Standard) (ICI 128436 (Standard)) is the analytical standard of Ponalrestat (HY-106697). This product is intended for research and analytical applications. Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 72702-95-5
- Formel: C17H12BrFN2O3
- Molecular Weight:391.19
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Ki: 7.7 nM (ALR2) and 60 μM (ALR1)[1]
Chemical Information
-
CAS. Nr. 72702-95-5
-
Molecular Weight 391.19
-
Formel C17H12BrFN2O3
-
SMILES
OC(CC(C1=C2C=CC=C1)=NN(CC3=C(C=C(Br)C=C3)F)C2=O)=O
-
Synonyms
ICI 128436 (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Ward WH, et al. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem Pharmacol. 1990 Jan 15;39(2):337-46. [Content Brief]
[2]. Bresson E, et al. The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J Clin Endocrinol Metab. 2011 Jan;96(1):210-9. [Content Brief]
[3]. Calcutt NA, et al. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004 Apr;47(4):718-24. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)